Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | PTGES | O14684 | 2/20 | 1.00 |
| ▸ | ALOX5AP | P20292 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Licofelone SCHEMBL1843506 | 0.96 | PTGES (0.92) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| Licofelone SCHEMBL7737421 | 0.94 | PTGES (0.88) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| SCHEMBL9458992 | 0.93 | ALOX5 (0.86) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| SCHEMBL5560426 | 0.92 | PTGES (0.85) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| SCHEMBL13697422 | 0.92 | PTGES (0.85) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| SCHEMBL19499839 | 0.92 | PTGES (0.85) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| Licofelone SCHEMBL1394262 | 0.92 | PTGES (0.84) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| Licofelone SCHEMBL1393673 | 0.91 | PTGES (0.83) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| Licofelone SCHEMBL7738810 | 0.91 | PTGES (0.83) | ALOX5PTGS1PTGESALOX5APPTGS2 | |
| SCHEMBL4087247 | 0.91 | PTGES (0.83) | ALOX5PTGS1PTGESALOX5APPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260061062-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | UNIV NEBRASKA (US) | 2026-03-05 | — | — | US | claimed |
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | PARKER DANE K (US) | 2026-02-10 | — | — | US | claimed |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | PLUTO INC (KR) | 2025-10-30 | — | — | US | claimed |
| WO-2025137653-A1 | METHODS AND COMPOSITIONS OF POLYCYCLIC AND A DUAL ACTING NITROXIDE COMPOUNDS FOR TREATMENT OF FAT CELL ASSOCIATED DISEASES | MELLICELL, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| CN-119732949-A | Use of Licofelone and taxus medicine composition in treating solid tumor | 典晶医药(无锡)有限公司 | 2025-04-01 | — | — | CN | claimed |
| WO-2025035205-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A SUBSTITUTED THIOPHENE FUSED CYCLOHEXANONE DERIVATIVE AND A CYCLOOXYGENASE (COX) INHIBITOR, AND THEIR USE FOR THE TREATMENT OF PAIN | NEURASIC THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | claimed |
| US-20250041275-A1 | COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE | RAMBAM MED-TECH LTD. (IL) | 2025-02-06 | — | — | US | claimed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| EP-1505964-A1 | ANNELATED PYRROLE COMPOUNDS AS PROTON PUMP INHIBITORS FOR TREATING ULCER | MERCKLE GMBH (DE) | 2005-02-16 | — | — | EP | claimed |
| US-20050004108-A1 | Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degenaration | MERCKLE GMBH (DE) | 2005-01-06 | — | — | US | claimed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| EP-1427410-A1 | USE OF ANNELLATED PYRROLE COMPOUNDS IN THE TREATMENT OF ARTICULAR CARTILAGE OR SUBCHONDRAL BONE DEGENERATION | MERCKLE GMBH (DE) | 2004-06-16 | — | — | EP | claimed |
| WO-2003097041-A1 | ANNELATED PYRROLE COMPOUNDS AS PROTON PUMP INHIBITORS FOR TREATING ULCER | MERCKLE GMBH (DE) | 2003-11-27 | — | — | WO | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| WO-2003020267-A1 | USE OF ANNELLATED PYRROLE COMPOUNDS IN THE TREATMENT OF ARTICULAR CARTILAGE OR SUBCHONDRAL BONE DEGENERATION | MERCKLE GMBH (DE) | 2003-03-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061062-A1 | MACROMOLECULAR PRODRUG-BASED THERMOSENSITIVE INJECTABLE GEL AS A NOVEL DRUG DELIVERY PLATFORM | CD44, ALG1, HSF1 | ALOX5 3180/4885PTGS1 59/4885PTGES 533/4885 |
| US-20250332143-A1 | COMPOSITION COMPRISING ALOX5 INHIBITOR FOR PREVENTING OR TREATING SARCOPENIA | MYOF, ALOX5, MYLK2 | ALOX5 2/4885PTGS1 893/4885PTGES 1682/4885 |
| US-20250041275-A1 | COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE | SLC10A2, SLC10A1, SLC2A2 | ALOX5 179/4885PTGS1 282/4885PTGES 190/4885 |
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | ALOX15, SOD1, ALOX12 | ALOX5 4/4885PTGS1 459/4885PTGES 73/4885 |
| US-20050004108-A1 | Use of annellated pyrrole compounds in the treatment of articular cartilage or subchondral bone degenaration | BMP4, COL2A1, ACP3 | ALOX5 2926/4885PTGS1 88/4885PTGES 710/4885 |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ASAH2, ASAH1, GBA2 | ALOX5 932/4885PTGS1 1433/4885PTGES 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.